CESM for Breast Cancer Detection
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial studies contrast enhanced spectral mammography (CESM) for the evaluation of pathologic nipple discharge. CESM is similar to standard mammography, but it includes an intravenous (by vein) injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. The goal of this trial is to learn if CESM, is better than standard mammography in quickly and efficiently determining the cause of nipple discharge and detecting breast cancer, if present. CESM may increase the chance of finding breast cancers and lower the risk of having unnecessary biopsies.
Do I need to stop my current medications for the CESM trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is CESM safe for humans?
How is the treatment CESM different from other breast cancer detection methods?
CESM (Contrast Enhanced Spectral Mammography) is unique because it combines a special contrast dye with traditional mammography to improve the detection of breast cancer, especially in women with dense breast tissue. This method enhances the visibility of tumors by highlighting areas of increased blood flow, which is often associated with cancer.45678
What data supports the effectiveness of the treatment Contrast Enhanced Spectral Mammography (CESM) for breast cancer detection?
Who Is on the Research Team?
Olena Weaver
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for women aged 25-85 with abnormal nipple discharge, who can have an IV placed and tolerate iodine contrast. It's not for those who've had recent breast biopsies or surgery near the nipple, known breast cancer, inflammation in the breast, are pregnant or breastfeeding within 6 months, allergic to iodine contrast, severe allergies of any kind without prior safe iodine contrast use, or kidney issues.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Imaging
Patients receive iodine-based contrast agent intravenously and undergo CESM over 10-15 minutes. Patients who have not undergone standard of care DBT within 3 months from the study, also undergo DBT.
Follow-up
Participants are monitored for outcomes such as the need for additional imaging, biopsies, and final pathologic results.
What Are the Treatments Tested in This Trial?
Interventions
- Contrast Enhanced Digital Mammography
- Iodinated Contrast Agent
Contrast Enhanced Digital Mammography is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor